Nuvectis Pharma Inc reports results for the quarter ended in June - Earnings Summary

Nuvectis Pharma

09/08/2023 14:25

* Nuvectis Pharma Inc  NVCT.OQ  reported a quarterly
adjusted loss
of 38 cents​​ per share for the quarter ended in June. The mean
expectation of three analysts for the quarter was for a loss
of 29 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Nuvectis Pharma Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 22% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Nuvectis Pharma Inc shares had fallen by 7.3% this
quarter and
gained 97.3% so far this year.
    * The company reported a quarterly loss of $5.71 million.
    * Wall Street's median 12-month price target for Nuvectis
Pharma
Inc is $20.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 01:25 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.29          -0.38          Missed
 Mar. 31 2023      -0.44          -0.27          Beat
 Dec. 31 2022      -0.38                         
 Sep. 30 2022      -0.27          -0.42          Missed